OncoMatch/Clinical Trials/NCT04085887
Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures
Is NCT04085887 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Panitumumab-IRDye800 and Pinpoint-IR9000 endoscopic/handheld device for brain tumor.
Treatment: Panitumumab-IRDye800 · Pinpoint-IR9000 endoscopic/handheld device · Explorer Air camera · PDE-NEO-II — The objective of the study is to assess safety of panitumumab-IRDye800 in pediatric patients undergoing brain surgery to remove suspected tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Cannot have received: investigational drug
Received an investigational drug within 30 days prior to first dose of Panitumumab IRDye800
Lab requirements
Blood counts
Magnesium, potassium and calcium < the lower limit of normal per institution normal lab values [excluded]
Kidney function
Serum creatinine > 1.5 times upper reference range [excluded]
Cardiac function
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); unstable angina within 6 months prior to enrollment; Evidence of QTc prolongation on pretreatment ECG (greater than 440 ms in children 1-8 years or 8-18 year old males or greater than 460 ms in infants up to 1 year or 8-18 year old females); Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment Evidence of QTc prolongation on pretreatment ECG (greater than 440 ms in children 1 8 years or 8 to 18 year old males or greater than 460 ms in infants up to 1 year or 8 to 18 year old females) Magnesium, potassium and calcium < the lower limit of normal per institution normal lab values Serum creatinine > 1.5 times upper reference range Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Cancer Center · Stanford, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify